Omega-3 and cardiovascular risk: what the REDUCE-IT trial actually means

Omega-3 (EPA) for cardiovascular risk: what the REDUCE-IT trial changed about the dosing conversation

High-dose EPA specifically, at 4 grams per day, reduced major cardiovascular events by 25% in a landmark placebo-controlled trial in people already on statins.

High-dose EPA specifically, at 4 grams per day, reduced major cardiovascular events by 25% in a landmark placebo-controlled trial in people already on statins.

Time to effect

Weeks (triglycerides); years (event reduction)

Weeks (triglycerides); years (event reduction)

Dose

For triglyceride lowering: ~1-2g/day combined EPA+DHA. For the REDUCE-IT-level cardiovascular effect: 4g/day prescription-grade EPA (icosapentaenoic acid), a prescription medication conversation

For triglyceride lowering: ~1-2g/day combined EPA+DHA. For the REDUCE-IT-level cardiovascular effect: 4g/day prescription-grade EPA (icosapentaenoic acid), a prescription medication conversation

Active compound

For event reduction: prescription EPA (Vascepa/icosapentaenoic acid); for triglycerides: standard combined EPA+DHA fish oil

For event reduction: prescription EPA (Vascepa/icosapentaenoic acid); for triglycerides: standard combined EPA+DHA fish oil

▪ The challenge at hand

Omega-3 fatty acids at standard supplement doses have produced inconsistent cardiovascular outcomes in trials, a pattern that confused the field for years. A large randomized trial (REDUCE-IT) clarified the picture in a way that matters for anyone taking omega-3 for heart health: it's high-dose EPA specifically, 4 grams per day, not standard-dose mixed EPA+DHA supplements at 1 gram per day, that produced a dramatic 25% reduction in major adverse cardiovascular events in people already on statin therapy.

The honest framing is that low-dose over-the-counter omega-3 supplements are not what this evidence is for, the trial used prescription-grade highly purified EPA (icosapentaenoic acid) at four times the dose in most supplements. This page clarifies that distinction while noting that DHA-containing fish oil at lower doses still has real support for reducing triglycerides, which is a separate, more accessible goal.

▪ What it is

Omega-3 fatty acids, particularly EPA (icosapentaenoic acid), for cardiovascular risk reduction, with two distinct evidence-based uses: standard-dose OTC fish oil for triglyceride reduction, and prescription-grade high-dose pure EPA for major cardiovascular event reduction in high-risk patients on statins.

Why this is surprising

Standard-dose mixed omega-3 supplements produced inconsistent cardiovascular trial results, creating confusion, until the REDUCE-IT trial clarified the picture: it's high-dose EPA specifically (4g/day, not 1g/day mixed EPA+DHA) that reduces major cardiovascular events by 25% in high-risk, statin-treated patients. The non-obvious implication: the OTC supplement you're taking for heart health is probably the wrong dose and the wrong form for this specific evidence base, though lower doses do genuinely reduce triglycerides, a separate goal with separate evidence.

▪ How it works

A plaque-stabilizing and anti-inflammatory effect at high dose.

High-dose EPA appears to work beyond simple triglyceride lowering, through anti-inflammatory, anti-thrombotic, and membrane-stabilizing effects on coronary artery plaques and arterial walls, including effects on plaque stability that may reduce vulnerability to rupture. The debate in the field is whether some of the effect is also due to the mineral oil placebo used in the trial (which may have slightly raised LDL in controls), but independent evidence for high-dose EPA across multiple endpoints supports a real cardiovascular benefit.

▪ The research

What the evidence says

REDUCE-IT, a randomized, placebo-controlled trial in 8,179 patients with elevated triglycerides and established cardiovascular disease or diabetes on statin therapy, found that prescription-grade high-purity EPA at 4g/day significantly reduced the primary composite cardiovascular endpoint by 25% (HR 0.75) compared with placebo over median 4.9-year follow-up. Standard-dose (~1g/day) mixed omega-3 supplements have shown more modest, inconsistent effects on cardiovascular events, though they consistently lower triglycerides by ~15-30%.

Bhatt DL et al. (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. PMID: 30415628. (Also: Harris WS, triglyceride-lowering with standard omega-3, Curr Opin Lipidol. 2007.)

WE'VE COACHED HUNDREDS OF USERS WITH THEIR CARDIOVASCULAR HEALTH

WE'VE COACHED HUNDREDS OF USERS WITH THEIR CARDIOVASCULAR HEALTH

Omega-3 (EPA) for cardiovascular risk, in practice

Omega-3 (EPA) for cardiovascular risk, in practice

Omega-3 (EPA) for cardiovascular risk, in practice

Long-term cardiovascular benefit is real but requires the patience to actually get there. Here's how it played out for people actually tracking it.

Long-term cardiovascular benefit is real but requires the patience to actually get there. Here's how it played out for people actually tracking it.

Long-term cardiovascular benefit is real but requires the patience to actually get there. Here's how it played out for people actually tracking it.

109

109

started

62%

62%

completed

42%

42%

noticed a change

16%

16%

made it routine

Self-reported by Coco users. Not a clinical outcome.

Self-reported by Coco users. Not a clinical outcome.

Data across the Coco Health user base, not a clinical outcome.

▪ What to look for

A practical buying guide

The REDUCE-IT evidence applies to prescription-grade high-purity EPA (sold as Vascepa in the US), not to OTC fish oil. For triglyceride reduction, standard OTC EPA+DHA products are appropriate at 1-2g/day. If you're a high-risk patient already on a statin, the event-reduction conversation belongs with your cardiologist, not the supplement aisle.

Coco is the AI health coach that runs experiments like this one with you

Know exactly what to do: Coco sets the protocol and checks in by call or message

See what's actually changing: Coco tracks your symptoms and synthesizes the trend

Get a real answer: Coco tells you whether the data supports continuing or stopping

▪ What to expect over time

Triglyceride reduction from standard fish oil appears within weeks of consistent use. The cardiovascular event reduction in the trial was measured over a median 4.9 years, reflecting a long-term risk-reduction trajectory rather than a short-term outcome.

Side effects

Fishy reflux, GI upset. Mild antiplatelet effect at higher doses, especially relevant at the 4g/day trial dose.

Who should be cautious

Monitor closely if you take anticoagulant medication, the blood-thinning effect is more significant at prescription doses. At high doses (4g/day), this is a prescription medication conversation, not a self-prescribed OTC approach. The OTC dose range (~1-2g/day) has a more favorable side-effect profile. Always consult a care provider when adding or removing a supplement from your routine.

FAQ

Can I just take more fish oil instead of getting a prescription?

Does fish oil at normal doses do anything for heart health?

Is Coco a replacement for my doctor?

Coco helps you turn health ideas like this into small, trackable experiments you can actually stick with.

The hard part isn't starting — it's knowing if it's working

Stay consistent: Coco checks in so you don't have to rely on motivation

See clearly: Coco reads your symptom data so you can trust what you're seeing

Get a real answer: Coco tells you whether it's working, even if it isn't

Educational only. This is not medical advice. Always talk with a qualified clinician before changing medications, supplements, or care plans.